{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T18:09:52Z","timestamp":1768586992723,"version":"3.49.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.lrr.2023.100371","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T12:10:58Z","timestamp":1685103058000},"page":"100371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia"],"prefix":"10.1016","volume":"19","author":[{"given":"Lyndsey","family":"Sandow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.lrr.2023.100371_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lrr.2023.100371_bib0002","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5045\/br.2013.48.3.178","article-title":"Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic\/myeloproliferative neoplasms","volume":"48","author":"Lim","year":"2013","journal-title":"Blood Res."},{"issue":"5","key":"10.1016\/j.lrr.2023.100371_bib0003","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the chronic malignancies working party of the European society for blood and marrow transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.lrr.2023.100371_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186862","article-title":"Atypical chronic myeloid leukemia: where are we now?","volume":"21","author":"Cris\u00e0","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.lrr.2023.100371_bib0005","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood-2013-06-509976","article-title":"The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition","volume":"122","author":"Fleischman","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.lrr.2023.100371_bib0006","first-page":"67","article-title":"Significant clinical response to JAK1\/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia","volume":"3","author":"Dao","year":"2014","journal-title":"Leuk. Res. Rep."},{"issue":"1","key":"10.1016\/j.lrr.2023.100371_bib0007","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/pbc.25694","article-title":"Atypical chronic myeloid leukemia in two pediatric patients","volume":"63","author":"Freedman","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"issue":"12","key":"10.1016\/j.lrr.2023.100371_bib0008","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat. Med."},{"issue":"414","key":"10.1016\/j.lrr.2023.100371_bib0009","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1690","article-title":"A precision therapy against cancers driven by KIT\/PDGFRA mutations","volume":"9","author":"Evans","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.lrr.2023.100371_bib0010","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41591-021-01539-8","article-title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","volume":"27","author":"Gotlib","year":"2021","journal-title":"Nat. Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048923000110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:08:28Z","timestamp":1761959308000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048923000110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":10,"alternative-id":["S2213048923000110"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100371","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2023.100371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100371"}}